Oncorus, Inc. (ONCR)

NASDAQ: ONCR · IEX Real-Time Price · USD
1.27
-0.08 (-5.93%)
Jun 29, 2022 12:29 PM EDT - Market open
-5.93%
Market Cap 32.87M
Revenue (ttm) n/a
Net Income (ttm) -69.88M
Shares Out 25.88M
EPS (ttm) -2.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 18,414
Open 1.30
Previous Close 1.35
Day's Range 1.25 - 1.30
52-Week Range 0.98 - 14.87
Beta n/a
Analysts Buy
Price Target 9.79 (+670.9%)
Earnings Date Aug 3, 2022

About ONCR

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca ... [Read more...]

Industry Biotechnology
IPO Date Oct 2, 2020
Employees 82
Stock Exchange NASDAQ
Ticker Symbol ONCR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for ONCR stock is "Buy." The 12-month stock price forecast is 9.79, which is an increase of 670.87% from the latest price.

Price Target
$9.79
(670.87% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Oncorus Appoints Douglas Fambrough to Board of Directors

-Former CEO of Dicerna brings deep expertise in RNA research, drug development, business development and financing-

Oncorus to Present at the Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced...

Oncorus to Present at the H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced ...

Oncorus Reports First Quarter 2022 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today reported f...

Oncorus Presents Preclinical Data on ONCR-021 and ONCR-788 Supporting Selectively Self-Amplifying vRNA Immunotherapy ...

– ONCR-021 and ONCR-788 demonstrate robust preclinical anti-tumor efficacy following IV-administration –

Oncorus Announces Debt Capital Facility with K2 HealthVentures with $20 Million Funded at Closing, Relocation of Corp...

-Multiple tranche debt financing agreement provides Oncorus with access to up to $45 million-

Oncorus to Present at the Maxim Group 2022 Virtual Growth Conference

CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announce...

Oncorus Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today reported...

Oncorus to Present at the H.C. Wainwright BioConnect Virtual Conference

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced...

Oncorus to Present at the Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced...

Why Did Oncorus Shares Slump To 52-Week Low Today?

Oncorus Inc (NASDAQ: ONCR) shares slumped after the company reported initial data for its investigational cancer therapy ONCR-177 from a Phase 1 trial in heavily pretreated patients with advanced, injec...

Why Oncorus Stock Is Crashing Today

The company announced initial data from a phase 1 study.

Oncorus, Gaeta Therapeutics Ink Cancer Candidate Licensing Agreement

Oncorus Inc (NASDAQ: ONCR) has signed an exclusive licensing agreement with Gaeta Therapeutics Ltd, related to the use of locally delivered Interleukin-12 (IL-12) via oncolytic viral expression in combi...

Wall Street Analysts Predict a 201% Upside in Oncorus, Inc. (ONCR): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 200.7% in Oncorus, Inc. (ONCR). While the effectiveness of this highly sought-after metric is questionable, the p...

Oncorus Reports Third Quarter 2021 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today reported ...

Oncorus Reports Second Quarter 2021 Financial Results and Provides Business Highlights

CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today reported ...

Oncorus Expands its Board with Appointment of Barbara Yanni

-- Former Merck executive brings extensive experience in corporate development, licensing and  financial evaluation, and expertise advising clinical stage public biopharmaceutical companies -- CAMBRIDGE...

Oncorus Appoints Eric Rubin, M.D. to its Board of Directors

-- Renowned academic and industry leader brings deep expertise in oncology translational research and drug development, including pioneering work at Merck on KEYTRUDA® (pembrolizumab) -- CAMBRIDGE, Mass...

Oncorus to Host Investor Day Featuring its IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Platform and Lead...

CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced...

Oncorus Announces Nomination of its First IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Product Candidates...

CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced ...

Oncorus to Present at Upcoming Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced ...

Oncorus Reports First Quarter 2021 Financial Results and Provides Business Highlights

-- Enrollment continues in Phase 1 clinical trial of lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate ONCR-177; initial interim data expected in 2H'21 -- -- Company plans to nomi...

The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.

7 of the Best Swing Trade Stocks Available Right Now

These are 7 of the best swing trade stocks on the market right now, but you need to have a strategy and rules in order to be safe. The post 7 of the Best Swing Trade Stocks Available Right Now appeared ...

Other symbols: GOOGLGSLMBPDULXLREGOOG

Oncorus Secures $57M Via Equity At 9% Discount

Oncorus Inc (NASDAQ: ONCR) prices of its underwritten public offering of 3 million common shares at $19 per share, raising $57 million in gross proceeds. The offer price represents a discount of 9% on t...